Krystal Biotech presents long-term B-VEC data showing durable wound healing in DEB patients

Krystal Biotech, Inc.

DDEB patient treated >2 years and RDEB patient >3 years with weekly topical B-VEC.
RDEB patient's wound burden decreased 80-90%, reverted from severe to intermediate generalized phenotype.
No significant adverse events attributed to B-VEC; treatment well tolerated.
RDEB patient showed systemic improvements: increased height, weight, and serum albumin levels.
Data presented at ISID meeting in Tokyo, May 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.